Alessandra Longhi1, Costantino Errani2, Marco Gambarotti3, Christina Ferrari3, Jennifer Kreshak2, Georgios N Panagopoulos4, Andreas F Mavrogenis5, Davide Donati2. 1. Department of Medical Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy. alessandra.longhi@ior.it. 2. Fourth Department of Orthopaedics, Istituto Ortopedico Rizzoli, Bologna, Italy. 3. Department of Pathology, Istituto Ortopedico Rizzoli, Bologna, Italy. 4. First Department of Orthopaedics, Attikon University Hospital, Athens University Medical School, Athens, Greece. 5. First Department of Orthopaedics, Attikon University Hospital, Athens University Medical School, Athens, Greece. afm@otenet.gr.
Abstract
PURPOSE: Second malignant neoplasms (SMN) or second cancers may occur in 2-5 % of childhood cancer survivors within 5-25 years after diagnosis and treatment of a bone sarcoma. The most common are leukemia and breast cancer; salivary gland SMN are exceptional. To enhance the literature, we reviewed our patients with bone sarcomas and evaluated the incidence and outcome of salivary gland SMN. MATERIALS AND METHODS: We retrospectively studied all patients with osteosarcoma and Ewing's sarcoma treated at the Istituto Ortopedico Rizzoli with chemotherapy from January 1983 to December 2012. There were 883 osteosarcoma and 543 Ewing's sarcoma patients. We evaluated the date of diagnosis and histology of bone sarcoma, chemotherapy administered, date of diagnosis and histology of SMN, and survival of patients. RESULTS: The 10-year incidence of SMN was 3.6 %; the most common were breast cancer, leukemia, sarcomas, and salivary gland neoplasms. The incidence of salivary gland SMN was 0.5 %; there were five male and two female patients with a mean age of 19 years (range 13-28 years) who experienced a salivary gland SMN within a mean interval of 79 months (range 51-97 months). The most common salivary gland involved was the parotid followed by the submandibular gland. One of the seven patients with salivary gland SMN died from his SMN. CONCLUSIONS: Treating physicians should be aware of the risk of salivary gland SMN after chemotherapy for bone sarcomas in children and adolescents. Close follow-up of childhood bone sarcoma survivors for SMN is important.
PURPOSE: Second malignant neoplasms (SMN) or second cancers may occur in 2-5 % of childhood cancer survivors within 5-25 years after diagnosis and treatment of a bone sarcoma. The most common are leukemia and breast cancer; salivary gland SMN are exceptional. To enhance the literature, we reviewed our patients with bone sarcomas and evaluated the incidence and outcome of salivary gland SMN. MATERIALS AND METHODS: We retrospectively studied all patients with osteosarcoma and Ewing's sarcoma treated at the Istituto Ortopedico Rizzoli with chemotherapy from January 1983 to December 2012. There were 883 osteosarcoma and 543 Ewing's sarcomapatients. We evaluated the date of diagnosis and histology of bone sarcoma, chemotherapy administered, date of diagnosis and histology of SMN, and survival of patients. RESULTS: The 10-year incidence of SMN was 3.6 %; the most common were breast cancer, leukemia, sarcomas, and salivary gland neoplasms. The incidence of salivary gland SMN was 0.5 %; there were five male and two female patients with a mean age of 19 years (range 13-28 years) who experienced a salivary gland SMN within a mean interval of 79 months (range 51-97 months). The most common salivary gland involved was the parotid followed by the submandibular gland. One of the seven patients with salivary gland SMN died from his SMN. CONCLUSIONS: Treating physicians should be aware of the risk of salivary gland SMN after chemotherapy for bone sarcomas in children and adolescents. Close follow-up of childhood bone sarcoma survivors for SMN is important.
Entities:
Keywords:
Chemotherapy; Ewing’s sarcoma; Osteosarcoma; Salivary gland neoplasms; Second cancer
Authors: Mark Bernstein; Heinrich Kovar; Michael Paulussen; R Lor Randall; Andreas Schuck; Lisa A Teot; Herbert Juergens Journal: Oncologist Date: 2006-05
Authors: Patrick Hundsdoerfer; Marion Albrecht; Ursula Rühl; Rüdiger Fengler; Andreas E Kulozik; Günter Henze Journal: Eur J Cancer Date: 2009-09 Impact factor: 9.162
Authors: J F McIntyre; B Smith-Sorensen; S H Friend; J Kassell; A L Borresen; Y X Yan; C Russo; J Sato; N Barbier; J Miser Journal: J Clin Oncol Date: 1994-05 Impact factor: 44.544
Authors: Daniel N Rutigliano; Paul Meyers; Ronald A Ghossein; Diane L Carlson; Mark L Kayton; Dennis Kraus; Michael P La Quaglia Journal: J Pediatr Surg Date: 2007-07 Impact factor: 2.545